162 related articles for article (PubMed ID: 26755002)
41. Amplification of the epidermal growth factor receptor gene in glioblastoma: an analysis of the relationship between genotype and phenotype by CISH method.
Miyanaga T; Hirato J; Nakazato Y
Neuropathology; 2008 Apr; 28(2):116-26. PubMed ID: 18021194
[TBL] [Abstract][Full Text] [Related]
42. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
[TBL] [Abstract][Full Text] [Related]
43. Chromogenic in situ hybridization accurately identifies EGFR amplification in small cell glioblastoma multiforme, a common subtype of primary GBM.
Quezado M; Ronchetti R; Rapkiewicz A; Santi M; Blumenthal DT; Rushing EJ
Clin Neuropathol; 2005; 24(4):163-9. PubMed ID: 16033132
[TBL] [Abstract][Full Text] [Related]
44. [Mutations of p53 gene in 41 cases of human brain gliomas].
Cui W; Kong X; Cao HL; Wang X; Gao JF; Wu RL; Wang XC
Ai Zheng; 2008 Jan; 27(1):8-11. PubMed ID: 18184456
[TBL] [Abstract][Full Text] [Related]
45. Epidermal growth factor receptor expression in oligodendroglial tumors.
Reifenberger J; Reifenberger G; Ichimura K; Schmidt EE; Wechsler W; Collins VP
Am J Pathol; 1996 Jul; 149(1):29-35. PubMed ID: 8686753
[TBL] [Abstract][Full Text] [Related]
46. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas.
Puputti M; Tynninen O; Sihto H; Blom T; Mäenpää H; Isola J; Paetau A; Joensuu H; Nupponen NN
Mol Cancer Res; 2006 Dec; 4(12):927-34. PubMed ID: 17189383
[TBL] [Abstract][Full Text] [Related]
47. Fluorescence in situ hybridization for 1p, 19q status in a cohort of glial neoplasms.
Singh VY; Chacko G; Chacko AG; Rajshekhar V
Neurol India; 2014; 62(1):32-6. PubMed ID: 24608451
[TBL] [Abstract][Full Text] [Related]
48. Prognostic stratification of patients with anaplastic gliomas according to genetic profile.
Dehais C; Laigle-Donadey F; Marie Y; Kujas M; Lejeune J; Benouaich-Amiel A; Pedretti M; Polivka M; Xuan KH; Thillet J; Delattre JY; Sanson M
Cancer; 2006 Oct; 107(8):1891-7. PubMed ID: 16986124
[TBL] [Abstract][Full Text] [Related]
49. Molecular genetics of radiographically defined de novo glioblastoma multiforme.
Tortosa A; Ino Y; Odell N; Swilley S; Sasaki H; Louis DN; Henson JW
Neuropathol Appl Neurobiol; 2000 Dec; 26(6):544-52. PubMed ID: 11123721
[TBL] [Abstract][Full Text] [Related]
50. Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis.
Chen JR; Xu HZ; Yao Y; Qin ZY
Acta Neurol Scand; 2015 Nov; 132(5):310-22. PubMed ID: 25846813
[TBL] [Abstract][Full Text] [Related]
51. Association between epidermal growth factor receptor amplification and ADP-ribosylation factor 1 methylation in human glioblastoma.
López-Ginés C; Navarro L; Muñoz-Hidalgo L; Buso E; Morales JM; Gil-Benso R; Gregori-Romero M; Megías J; Roldán P; Segura-Sabater R; Almerich-Silla JM; Monleón D; Cerdá-Nicolás M
Cell Oncol (Dordr); 2017 Aug; 40(4):389-399. PubMed ID: 28631186
[TBL] [Abstract][Full Text] [Related]
52. IDH1 mutation of gliomas with long-term survival analysis.
Myung JK; Cho HJ; Park CK; Kim SK; Phi JH; Park SH
Oncol Rep; 2012 Nov; 28(5):1639-44. PubMed ID: 22922798
[TBL] [Abstract][Full Text] [Related]
53. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
Ogura R; Tsukamoto Y; Natsumeda M; Isogawa M; Aoki H; Kobayashi T; Yoshida S; Okamoto K; Takahashi H; Fujii Y; Kakita A
Neuropathology; 2015 Aug; 35(4):324-35. PubMed ID: 25950388
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy.
Marquez A; Wu R; Zhao J; Tao J; Shi Z
Diagn Mol Pathol; 2004 Mar; 13(1):1-8. PubMed ID: 15163002
[TBL] [Abstract][Full Text] [Related]
55. Apoptosis and p53 expression in human gliomas.
Sipos L; Szegedi Z; Fedorcsák I; Afra D; Szende B
Pathol Oncol Res; 1998; 4(4):267-70. PubMed ID: 9887356
[TBL] [Abstract][Full Text] [Related]
56. The role of immunohistochemistry in predicting behavior of astrocytic tumors.
Ambroise MM; Khosla C; Ghosh M; Mallikarjuna VS; Annapurneswari S
Asian Pac J Cancer Prev; 2010; 11(4):1079-84. PubMed ID: 21133628
[TBL] [Abstract][Full Text] [Related]
57. p53 mutation, EGFR gene amplification and loss of heterozygosity on chromosome 10, 17 p in human gliomas.
Jin W; Xu X; Yang T; Hua Z
Chin Med J (Engl); 2000 Jul; 113(7):662-6. PubMed ID: 11776043
[TBL] [Abstract][Full Text] [Related]
58. Clinicopathological factors predictive of postoperative seizures in patients with gliomas.
Yang P; Liang T; Zhang C; Cai J; Zhang W; Chen B; Qiu X; Yao K; Li G; Wang H; Jiang C; You G; Jiang T
Seizure; 2016 Feb; 35():93-9. PubMed ID: 26808114
[TBL] [Abstract][Full Text] [Related]
59. Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.
Hinrichs BH; Newman S; Appin CL; Dunn W; Cooper L; Pauly R; Kowalski J; Rossi MR; Brat DJ
Acta Neuropathol Commun; 2016 Jan; 4():4. PubMed ID: 26757882
[TBL] [Abstract][Full Text] [Related]
60. Epidermal growth factor receptor gene amplification and expression in disseminated pediatric low-grade gliomas.
Tabori U; Rienstein S; Dromi Y; Leider-Trejo L; Constantini S; Burstein Y; Dvir R; Amariglio N; Toren A; Rechavi G; Izraeli S; Aviram A
J Neurosurg; 2005 Oct; 103(4 Suppl):357-61. PubMed ID: 16270688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
